INT25136

Context Info Confidence 0.75 First Reported 1989 Last Reported 2010 Negated 1 Speculated 0 Reported most in Body Documents 23 Total Number 23 Disease Relevance 5.01 Pain Relevance 3.65

signal transduction (Gnat3) GTPase activity (Gnat3) cytoplasm (Gnat3) signal transducer activity (Gnat3)

Anatomy Link Frequency blood 2 EPI 2 plasma 1 SOL 1 heart 1 Gnat3 (Mus musculus)

Pain Link Frequency Relevance Heat Calcitonin gene-related peptide 7 99.96 transdermal 14 99.82 cva 12 99.72 IPN 4 99.30 headache 9 98.92 tolerance 86 98.76 Angina 16 95.24 Bioavailability 20 93.12 Pain 29 93.00 Migraine 2 86.80

Disease Link Frequency Relevance Heat Cv General 3 Under Development 22 99.72 Increased Venous Pressure Under Development 40 99.64 Pressure And Volume Under Development 13 99.26 Hypertension 15 99.24 Cv Unclassified Under Development 12 97.32 Myocardial Infarction 4 96.64 INFLAMMATION 46 96.52 Pressure Volume 2 Under Development 4 95.52 Pain 25 93.00 Hypertrophy 15 92.80

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Interpenetrating polymer network (IPN)-structured hydrogels of gelatin (Gtn) and dextran (Dex) were prepared with lipid microspheres (LMs) as a drug microreservoir, and LM release from these hydrogels was examined in relation to their dual-stimuli-responsive degradation.

Localization (release) of Gtn associated with ipn

1) Confidence 0.75 Published 1998 Journal J Control Release Section Abstract Doc Link 9724906 Disease Relevance 0 Pain Relevance 0.27

In a placebo-controlled double-blind study, two GTN patches each releasing 7.5 mg GTN were applied.

Localization (releasing) of GTN

2) Confidence 0.61 Published 1989 Journal Eur. Heart J. Section Abstract Doc Link 2501094 Disease Relevance 0.35 Pain Relevance 0.21

STUDY DESIGN: The transdermal patches (Minitran S10) releasing GTN were used for the treatment of 27 pregnancies between 27-34 weeks admitted for hypertension above 150/100 mmHg.

Localization (releasing) of GTN

3) Confidence 0.61 Published 2004 Journal Ginekol. Pol. Section Body Doc Link 15108586 Disease Relevance 0.09 Pain Relevance 0

[Effect of long-term therapy with transdermal patches releasing glyceryl trinitrate (GTN) used in pregnant hypertensive women on stabilisation of blood pressure and on the condition of the newborn infant].

Localization (releasing) of GTN in blood associated with transdermal, hypertension and headache

4) Confidence 0.61 Published 2004 Journal Ginekol. Pol. Section Title Doc Link 15108586 Disease Relevance 0.10 Pain Relevance 0.19

OBJECTIVE: An observation of an influence of long-term therapy of pregnant women affected by arterial hypertension with transdermal patches releasing GTN on stabilisation of blood pressure and newborn condition.

Localization (releasing) of GTN in blood associated with pressure and volume under development and transdermal

5) Confidence 0.61 Published 2004 Journal Ginekol. Pol. Section Abstract Doc Link 15108586 Disease Relevance 0.17 Pain Relevance 0.09

No side effects of long-term therapy with patches releasing GTN were observed among the newborns.

Localization (releasing) of GTN

6) Confidence 0.61 Published 2004 Journal Ginekol. Pol. Section Body Doc Link 15108586 Disease Relevance 0.06 Pain Relevance 0

In a placebo-controlled double-blind study, two GTN patches each releasing 7.5 mg GTN were applied.

Localization (releasing) of GTN

7) Confidence 0.61 Published 1989 Journal Eur. Heart J. Section Abstract Doc Link 2501094 Disease Relevance 0.35 Pain Relevance 0.21

This patch provides a biphasic GTN release profile with therapeutic GTN plasma concentrations developing soon after application and persisting for 12h, but with low plasma concentrations during the remainder of the 24h period.

Localization (release) of GTN in plasma

8) Confidence 0.61 Published 1989 Journal Eur. Heart J. Section Abstract Doc Link 2501094 Disease Relevance 0.21 Pain Relevance 0.14

This profile of GTN release was designed to avoid nitrate tolerance by providing a low nitrate period for substantial periods during each 24-h application period.

Localization (release) of GTN associated with tolerance

9) Confidence 0.61 Published 1989 Journal Eur. Heart J. Section Abstract Doc Link 2501094 Disease Relevance 0.31 Pain Relevance 0.20

This action may be related to the nitric oxide released from GTN, through a direct action on the vein and the surrounding inflamed tissue.

Localization (released) of GTN in vein

10) Confidence 0.51 Published 1994 Journal Angiology Section Abstract Doc Link 8172381 Disease Relevance 1.20 Pain Relevance 0.42

The GTN was isolated and severed at the Achilles tendon and the distal two thirds of the GTN removed leaving the PLN and SOL muscles and their blood and nerve supply intact.

Localization (severed) of GTN in SOL

11) Confidence 0.43 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2905373 Disease Relevance 0.34 Pain Relevance 0.05

Because GTN does not release NO spontaneously, it requires bioconversion.

Neg (NO) Localization (release) of GTN

12) Confidence 0.35 Published 2008 Journal The Journal of Biological Chemistry Section Body Doc Link PMC2576553 Disease Relevance 0.19 Pain Relevance 0.14

Chronic application of GTN is severely hampered by the phenomenon of nitrate tolerance.

Localization (application) of GTN associated with tolerance

13) Confidence 0.32 Published 2008 Journal The Journal of Biological Chemistry Section Body Doc Link PMC2576553 Disease Relevance 0.09 Pain Relevance 0.22

Activities of ALDH2 after GTN Preconditioning—In the experiments described so far, we studied the inactivation of ALDH in real time by monitoring the dehydrogenase and esterase activities in the presence of GTN.

Localization (presence) of GTN

14) Confidence 0.32 Published 2008 Journal The Journal of Biological Chemistry Section Body Doc Link PMC2576553 Disease Relevance 0 Pain Relevance 0

After preincubation, the mixture was centrifuged (15,000 × g, 5 min at 4 °C) and washed three times with Tris buffer to remove GTN.

Localization (remove) of GTN

15) Confidence 0.32 Published 2008 Journal The Journal of Biological Chemistry Section Body Doc Link PMC2576553 Disease Relevance 0 Pain Relevance 0

At higher concentrations, GTN and the thiol reductant (here represented by DTT) compete for the oxidized thiyl state, resulting in direct regeneration of the reduced enzyme with DTT, or in irreversible inactivation with GTN (ESH, ES-, ES-S, and Ei represent the reduced (thiol/thiolate), oxidized thiyl, oxidized disulfide, and irreversibly inactivated enzyme states; kox, krev, kirr, kred, and kred?

Localization (represented) of GTN

16) Confidence 0.32 Published 2008 Journal The Journal of Biological Chemistry Section Body Doc Link PMC2576553 Disease Relevance 0 Pain Relevance 0

The three strengths coded in this paper EPI-5, EPI-10 and EPI-15 have a nominal release rate of GTN of 5, 10 and 15 mg, respectively, in 24 h.

Localization (release) of GTN in EPI

17) Confidence 0.25 Published 2000 Journal Arzneimittelforschung Section Abstract Doc Link 11050694 Disease Relevance 0 Pain Relevance 0.13

Kinetics of ALDH2 Inactivation by GTN

Localization (Kinetics) of GTN

18) Confidence 0.20 Published 2010 Journal The Journal of Biological Chemistry Section Body Doc Link PMC2801295 Disease Relevance 0 Pain Relevance 0

At a concentration of 1 mm, NAD had a less pronounced effect on GTN denitration by ALDH2*2 (?

Localization (denitration) of GTN

19) Confidence 0.17 Published 2010 Journal The Journal of Biological Chemistry Section Body Doc Link PMC2801295 Disease Relevance 0 Pain Relevance 0

Maximal GTN reductase activity (30 ± 2.4 nmol × min?

Localization (Maximal) of GTN

20) Confidence 0.17 Published 2010 Journal The Journal of Biological Chemistry Section Body Doc Link PMC2801295 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.